AstraZeneca Pharma India files writ petition in Delhi High Court against NPPA demand notice
The notice of demand alleges that the company has overcharged about Rs 157.38 crore from March 8, 2019 to January 31, 2021, for Tagrisso (Osimertinib) 80 mg tablets.
July 1, 2021
by expresspharma
EU clears Tagrisso for early-stage EGFR-mutated lung cancer
The European Commission (EC) has approved AstraZeneca’s (AZ) Tagrisso for the adjuvant treatment of early-stage, epidermal growth factor receptor mutated (EGFR) non-small cell lung cancer (NSCLC) following surgery.
June 1, 2021
by pharmatimes
AZ' Tagrisso first to win MHRA approval under Project Orbis
AstraZeneca's Tagrisso (osimertinib), a post-surgery treatment for lung cancer, is the first drug to receive approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) under Project Orbis.
May 8, 2021
by pharmatimes
Tagrisso moves closer towards EU approval for early-stage lung cancer
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s (AZ) Tagrisso for approval in the EU for the treatment of early-stage lung cancer patients.
April 29, 2021
by pharmatimes
FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer
The U.S. Food and Drug Administration (FDA) approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
December 23, 2020
by americanpharmaceuticalreview
Green light for AZ’s Tagrisso in early-stage lung cancer
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Tagrisso (osimertinib) for the treatment of adult patient with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
December 22, 2020
by pharmatimes
AZ’s Tagrisso scores priority review from FDA
AstraZeneca’s EGFR-tyrosine kinase inhibitor Tagrisso has been granted a priority review by the US Food and Drug Administration (FDA) for the treatment of early-stage EGFR-mutated lung cancer.
October 22, 2020
by pharmatimes
NICE backing for AZ' Tagrisso
AstraZeneca's Tagrisso (osimertinib) has been recommended for use within NHS England, in line with its licensed indication, for adults with untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) ...
September 15, 2020
by pharmatimes
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402) ...
August 11, 2020
by pharmaceutical-business-review
TAGRISSO granted FDA breakthrough therapy status in EGFR-mutated lung cancer
AstraZeneca’s TAGRISSO (osimertinib) has been granted Breakthrough Therapy Designation (BTD) in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer...
August 5, 2020
by pharmaceutical-business-review
Tagrisso shows 'unprecedented' disease free survival in lung cancer
According to AstraZeneca, its EGFR inhibitor Tagrisso (osimertinib) has shown 'unprecedented disease-free survival' in the adjuvant treatment of patients with EGFR-mutated lung cancer.
June 1, 2020
by pharmatimes
China grants Tagrisso (osimertinib) marketing authorisation
Following positive clinical trials, the Tagrisso drug has been given marketing authorisation in China for treatment of NSCLC.
September 6, 2019
by europeanpharmaceuticalreview